Yes I'm looking forward to seeing the first prostate data since we know nothing about how it's going except the trial moved forward beyond the initial dosage testing. I cautiously view DOs interview comment that AXAL has shown it will work well with either Merck or Astras PD1. The bullish interpretation is that Merck has potentially stepped up to do a deal with ADXS on both prostate and AXAL cancers because they like what they have seen in the prostate combo trips. The negative interpretation, which I hope is not the case, is that the prostate combo trial is not looking so good so DO is focused on getting a deal on AXAL with either Merck or Astra seeing that the Merck prostate combo trial will not result in a deal. Thoughts?
News 
Market Data 
Discover 
AI
